$1,756.48 general Payment -- Amgen Inc to Dr. Jessica Moore

Amgen Inc. compensates Rheumatologist Jessica Moore $1,756.48 for services related to Tecfidera.

This page provides a detailed analysis of a $1,756.48 general payment from Amgen Inc to Dr. Jessica Moore. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$1,756.48
Payment Typegeneral
Payment NatureCompensation for services other than consulting
Pharmaceutical CompanyAmgen Inc
PhysicianDr. Jessica Moore
NPI Number1869425750
Physician SpecialtyRheumatology
LocationWorcester, MA
Date of Payment2024-10-12
Related Drug/DeviceTecfidera
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Amgen Inc made a $1.8K general payment to Jessica Moore, a Rheumatology specialist in Worcester, MA. The payment was associated with Tecfidera. The payment of $1,756.48 to Dr. Jessica Moore from Amgen Inc. is for services other than consulting. This payment is associated with the drug Tecfidera, commonly used in rheumatology. The payment was made on October 12, 2024, in Worcester, MA.

Patient Guidance: What This Payment Means for You

This information details a payment made to your healthcare provider for services. It is important to discuss any treatment decisions directly with your doctor. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for services other than consulting in Rheumatology can vary widely depending on the nature of the services rendered and the specific agreements between physicians and pharmaceutical companies.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Physician Payments Sunshine Act, a provision of the Affordable Care Act, requiring disclosure of financial relationships between drug and device manufacturers and physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $1.8K payment for?

This was a general payment of $1.8K from Amgen Inc to Jessica Moore, categorized as "Compensation for services other than consulting". It was associated with Tecfidera. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Jessica Moore accept pharmaceutical money?

Yes, Jessica Moore received this $1.8K payment from Amgen Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Jessica Moore's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $1.8K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Rheumatology?

To compare this payment against Rheumatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rheumatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Jessica Moore's relationship with Amgen Inc?

The payment is categorized as 'general' and specifically for 'Compensation for services other than consulting'. This $1.8K general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Rheumatology?

Dr. Moore's specialty is Rheumatology, and the associated drug is Tecfidera.

What should patients do after learning about this payment?

This information details a payment made to your healthcare provider for services. It is important to discuss any treatment decisions directly with your doctor.

What else should I know about this general payment?

The payment ID is OP-MNJ1DDSD-TF9YNL, and the NPI is 1869425750.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.